Clinical & translational oncology

• 

  Año 2014, Vol. 16, Número 10

  • TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Manuel Benavides Orgaz, Albert Abad Esteve, I. Ales Díaz, Alfredo Carrato Mena, Eduardo Díaz-Rubio García, Javier Gallego Plazas, Jesús García-Foncillas López, Cristina Grávalos Castro, Berta Laquente Sáez, Carles Pericay Pijaume, Fernando Rivera Herrero, Josep Tabernero Caturla, Enrique Aranda Aguilar

    • Resumen

    págs. 465-478

    

  • New biological markers in the decision of treatment of head and neck cancer patients

    Almudena Valenciano Folgado, Luis Alberto Henríquez Hernández, Marta Lloret Sáez-Mravo, B. Pinar, Pedro Lara Jiménez

    • Resumen

    págs. 849-858

    

  • Subcutaneous trastuzumab: drug development and current position

    Paloma Martín Martorell, Begoña Bermejo de las Heras, José Alejandro Pérez Fidalgo, Marisol Huerta Alvaro, Miguel Martín Jiménez, Joan Albanell Mestres, Ana Lluch Hernández

    • Resumen

    págs. 859-864

    

  • Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk

    H.-Y. Zhao, H.-X. Duan, Y. Gu

    • Resumen

    págs. 879-885

    

  • High Sam68 expression predicts poor prognosis in non-small cell lung cancer

    Z. Zhang, Y. Xu, N. Sun, M. Zhang, J. Xie, Z. Jiang

    • Resumen

    págs. 886-891

    

  • Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations

    Amparo González Sanchis, A. Vicedo-González, Luis Brualla Gonzalez, Jose Carlos Gordo Partearroyo, R. Iñigo-Valdenebro, José Luis Sánchez Carazo, D. Granero-Cabañero, Joan Roselló Ferrando, José López Torrecilla

    • Resumen

    págs. 892-897

    

  • Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells

    Y. L. Xie, Y. J. Yang, C. Tang, H. J. Sheng, Y. Jiang, K. Han, L. J. Ding

    • Resumen

    págs. 898-905

    

  • Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer

    L. Zhou, D. Xia, J. Zhu, Y. Chen, G. Chen, R. Mo, Y. Zeng, Q. Dai, H. He, Y. Liang, F. Jiang, W. Zhong

    • Resumen

    págs. 906-913

    

  • Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Carlos Camps Herrero, Luis Paz-Ares Rodríguez, M. Codes Manuel de Villena, Rafael López López, A. Antón Torres, Pedro Gascón Vilaplana, Vicente Guillem Porta, Alfredo Carrato Mena, Juan Jesús Cruz Hernández, Cristina Caballero Díaz, Ana Blasco Cordellat, J. A. Moreno Nogueira, Eduardo Díaz-Rubio García

    • Resumen

    págs. 914-920

    

  • Second primary malignancies in patients with neuroendocrine tumors

    J. J. Reina Zoiló, Raquel Serrano Blanch, M. Codes Manuel de Villena, Encarnacion Jiménez, M. Bolaños, Encarnación González Flores, Mª Isabel Sevilla García

    • Resumen

    págs. 921-926

    

  • Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana�s predictive model

    Andrés Jesús Muñoz Martín, Pilar García Alfonso, A. B. Rupérez Blanco, Sara Pérez Ramírez, Montserrat Blanco Codesido, Miguel Martín Jiménez

    • Resumen

    págs. 927-930

    

  • Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

    A. López González, Clara Salas Antón, Mariano Provencio Pulla, M. Córdoba, Carlos Gamallo Amat

    • Resumen

    págs. 931-934

    

  • Bevacizumab in advanced cervical cancer

    P. J. Vlachostergios, C. N. Papandreou

    pág. 935